Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.

Abstract:

:In this cross-sectional study, we compared the quality of life (QOL) in transfusion-dependent thalassemic patients who survived matched sibling hematopoietic SCT (HSCT, n=24) with patients treated conventionally with transfusion and iron chelation (n=74). WHOQOL-BREF(HK) and PedsQL questionnaires were administered to patients aged >18 years and 5-12 years, respectively. Patients aged 12-18 years received both questionnaires. WHOQOL-BREF(HK) revealed post transplant patients rated overall health better than those treated conventionally (score 3.67 vs 3.06, P=0.01). They are less dependent on medical aids (3.87 vs 2.96, P=0.006), having higher activity level (4.00 vs 3.36, P=0.026) and better personal relationships (4.13 vs 3.69, P=0.014). Physical health domain score was better (75.20 vs 63.94, P=0.007). These differences remained significant after adjustment for comorbidities. PedsQL revealed post transplant patients rated better for running (3.53 vs 2.72, P=0.001) and sports (3.20 vs 2.64, P=0.038), even after adjustment for comorbidities, but were less satisfied for school absence to attend hospital (2.53 vs 3.29, P=0.03). Post transplant patients were significantly more likely to consider marriage (100 vs 75.7%, P=0.033), but not childbearing (66.7 vs 51.4%, P=0.28). In conclusion, transplanted thalassemic patients enjoy better QOL, mainly in physical health, compared with conventionally treated patients. This information is important to patients considering HSCT.

journal_name

Bone Marrow Transplant

authors

Cheuk DK,Mok AS,Lee AC,Chiang AK,Ha SY,Lau YL,Chan GC

doi

10.1038/bmt.2008.165

subject

Has Abstract

pub_date

2008-09-01 00:00:00

pages

319-27

issue

5

eissn

0268-3369

issn

1476-5365

pii

bmt2008165

journal_volume

42

pub_type

杂志文章,多中心研究
  • Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.

    abstract::Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.234

    authors: Jedlickova Z,Schmid C,Koenecke C,Hertenstein B,Baurmann H,Schwerdtfeger R,Tischer J,Kolb HJ,Schleuning M

    更新日期:2016-05-01 00:00:00

  • Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.

    abstract::Leukemic relapse remains the most frequent reason for treatment failure in patients with acute myeloblastic leukemia (AML) treated with autologous blood stem cell transplantation (ABSCT). The aim of this study was to evaluate the possible role of autologous bone marrow transplant (ABMT) in patients with AML who relaps...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: de la Rubia J,Sanz GF,Martín G,Sempere A,Picón I,Carral A,Larrea L,Martínez J,Soler MA,Bonanad S,López F,Jarque I,Sanz MA

    更新日期:1996-12-01 00:00:00

  • Ruxolitinib treatment for GvHD in patients with myelofibrosis.

    abstract::Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.256

    authors: Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

    更新日期:2016-12-01 00:00:00

  • Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study.

    abstract::The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701419

    authors: Montagna D,Locatelli F,Calcaterra V,Comoli P,Moretta A,Giorgiani G,Zecca M,Bonetti F,Giraldi E,Rondini G,Maccario R

    更新日期:1998-10-01 00:00:00

  • Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants.

    abstract::Using in situ hybridization with an X and Y chromosome probe mixture, 106 bone marrow samples from 38 patients with malignant and non-malignant hematological diseases who received sex-mismatched allogeneic hematopoietic progenitor cell transplants (PCT) in a single institution within short-term intervals (1, 3, 6, 12,...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701816

    authors: Ortega M,Escudero T,Caballín MR,Olivé T,Ortega JJ,Coll MD

    更新日期:1999-07-01 00:00:00

  • Use of the BCR probe to demonstrate extramedullary recurrence of CGL with a T cell lymphoid phenotype following bone marrow transplantation.

    abstract::A case of Philadelphia chromosome (Ph1) positive chronic granulocytic leukemia (CGL) is described in which the patient underwent successful treatment with supralethal chemoradiotherapy and allogeneic bone marrow transplantation (BMT) after transformation to blast crisis. Supraclavicular adenopathy developed 5 months a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Giannone L,Whitlock JA,Kinney MC,Wolff SN,Dev VG

    更新日期:1988-11-01 00:00:00

  • Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis.

    abstract:SUMMARY:Encephalopathy is a poorly characterized complication of hematopoietic stem cell transplantation (HSCT). No comprehensive report of encephalopathy exists for children, and the literature contains only a few for adults. We analyzed a large cohort of 405 pediatric patients who underwent allogeneic HSCT during a 1...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704480

    authors: Woodard P,Helton K,McDaniel H,Khan RB,Thompson S,Hale G,Benaim E,Kasow K,Leung W,Horwitz E,Srivastava DK,Tong X,Yusuf U,Cunningham JM,Handgretinger R

    更新日期:2004-06-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract::Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期:1994-12-01 00:00:00

  • Disseminated fungal infection and early onset microangiopathy after allogeneic bone marrow transplantation.

    abstract::We report a patient who developed early onset microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after allogeneic bone marrow transplantation (BMT). The clinical features and laboratory findings were not consistent with cyclosporin toxicity, graft-versus-host disease or cytomegalovirus infection as causativ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Grigg A,Clouston D

    更新日期:1995-05-01 00:00:00

  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.

    abstract::When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Johnson BD,Drobyski WR,Truitt RL

    更新日期:1993-04-01 00:00:00

  • Minimal residual disease testing after stem cell transplantation for multiple myeloma.

    abstract::Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.164

    authors: Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

    更新日期:2016-01-01 00:00:00

  • Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.

    abstract::Acquired factor VII (FVII) deficiency in the absence of vitamin K deficiency, oral anticoagulant therapy, synthetic liver dysfunction, or DIC is rare, with only a handful of cases thus far reported. In the period from 1990 to 1996 we identified eight patients with acquired FVII deficiency, all of whom presented with p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703381

    authors: Toor AA,Slungaard A,Hedner U,Weisdorf DJ,Key NS

    更新日期:2002-03-01 00:00:00

  • Rescuing the neonatal brain from hypoxic injury with autologous cord blood.

    abstract::Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2012.169

    authors: Liao Y,Cotten M,Tan S,Kurtzberg J,Cairo MS

    更新日期:2013-07-01 00:00:00

  • Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.

    abstract::From August 1995 to December 1997, 15 patients with stage III-IV ovarian cancer were treated with outpatient intensive chemotherapy with G-CSF and stem cell support. The first cycle consisted of cyclophophamide IV 6 g/m(2); second, third, fourth and fifth paclitaxel 250 mg/m(2) and the sixth and seventh carboplatin AU...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703762

    authors: Viret F,Bertucci F,Genre D,Gravis G,Chabannon C,Conte M,Houvenaeghel G,Maraninchi D,Viens P

    更新日期:2002-12-01 00:00:00

  • Endocrine late effects in children who underwent bone marrow transplantation: review.

    abstract::With the increasing use and success of BMT, larger numbers of children survive transplantation. Still, cancer treatment in children causes damage to the endocrine glands, often inducing growth deficiency, pubertal delay and thyroid dysfunction. This paper will deal with some of the most common endocrine disorders rela...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Cohen A,Rovelli R,Zecca S,Van-Lint MT,Parodi L,Grasso L,Uderzo C

    更新日期:1998-04-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.

    abstract::Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.84

    authors: Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

    更新日期:2013-01-01 00:00:00

  • Influence of HLA-DPB1 mismatches on MLR responses: the role of high resolution HLA class II typing and MLC in unrelated donor selection for BMT.

    abstract::Twenty eight Hungarian patients lacking a compatible related donor and their 61 HLA-A,B,DR serologically identical potential unrelated donors (selected from BMDW) were investigated in this study. Out of the 61 donor-recipient pairs only 7 (11,5%) proved to be HLA-identical at DNA level. Thirty one pairs (50,8%) differ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Pénzes M,Rajczy K,Gyódi E,Petrányi GG

    更新日期:1998-12-01 00:00:00

  • Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.

    abstract::Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many cente...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.13

    authors: Phipps C,Linenberger M,Holmberg LA,Green D,Becker P,Connelly-Smith L,Klippel Z,Burwick N,Gopal A,Bensinger WI,Libby E

    更新日期:2015-05-01 00:00:00

  • Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

    abstract::We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days). The tim...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701646

    authors: Perry JJ,Fleming RA,Rocco MV,Petros WP,Bleyer AJ,Radford JE Jr,Powell BL,Hurd DD

    更新日期:1999-04-01 00:00:00

  • Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.

    abstract::Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705788

    authors: Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

    更新日期:2007-10-01 00:00:00

  • Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.

    abstract::Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of patients at high risk for relaps...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703262

    authors: Kumar S,Chen MG,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Tefferi A,Litzow MR

    更新日期:2001-11-01 00:00:00

  • Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

    abstract::Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,meta分析

    doi:10.1038/bmt.2016.222

    authors: Landgren O,Devlin S,Boulad M,Mailankody S

    更新日期:2016-12-01 00:00:00

  • Clonal imbalances of serum immunoglobulins after allogeneic bone marrow transplantation: an analysis by high-resolution two-dimensional gel electrophoresis.

    abstract::The clonality pattern of immunoglobulins (Igs) produced after allogeneic bone marrow transplantation (BMT) was studied by high-resolution two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of serum samples and purified Igs. With this technique, the light (L) chain of a monoclonal Ig usually appears as a sing...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tissot JD,Helg C,Chapuis B,Zubler RH,Jeannet M,Hochstrasser DF,Hohlfeld P,Schneider P

    更新日期:1992-10-01 00:00:00

  • Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.

    abstract::Lineage-specific chimerism studies are commonly obtained at several time points after nonmyeloablative hematopoietic cell transplantation to assess the tempo and degree of engraftment, and to monitor graft rejection. For patients who receive myeloablative transplants, the value of frequent chimerism analyses using sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.155

    authors: Doney K,Loken M,Bryant E,Smith A,Appelbaum F

    更新日期:2008-08-01 00:00:00

  • Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre.

    abstract::The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.104

    authors: Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

    更新日期:2010-01-01 00:00:00

  • Monitoring four herpesviruses in unrelated cord blood transplantation.

    abstract::Cord blood transplantation, which has lower risk of graft-versus-host disease than bone marrow transplantation, might have higher risk of infections. A system to quantify four herpesviruses, CMV, human herpesvirus 6 (HHV6), EBV, varicella-zoster virus using the real-time PCR assay was established and applied for prosp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702710

    authors: Tanaka N,Kimura H,Hoshino Y,Kato K,Yoshikawa T,Asano Y,Horibe K,Kojima S,Morishima T

    更新日期:2000-12-01 00:00:00

  • Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: two case reports and a review of the literature.

    abstract::Bone marrow (BM) histiocystosis in association with the administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) is a rare phenomenon with few published cases. We report two cases of BM histiocystosis in patients with Hodgkin's disease treated with GM-CSF after autologous bone marrow transplantation...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1701036

    authors: Al-Homaidhi A,Prince HM,Al-Zahrani H,Doucette D,Keating A

    更新日期:1998-01-01 00:00:00

  • Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation.

    abstract::Infection with human cytomegalovirus (HCMV) after allogeneic bone marrow transplantation (BMT) was studied in 12 HCMV seronegative recipients of marrow from seropositive donors by weekly monitoring of cultures, expression of HCMV antigenemia (pp65) in granulocytes, polymerase chain reaction (PCR) on HCMV-DNA in granul...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: de Gast GC,Boland GJ,Vlieger AM,de Weger RA,Verdonck LF,Zwaan FE,Jiwa NM

    更新日期:1992-04-01 00:00:00

  • Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

    abstract::As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n=7) and unrelated donors (n...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.85

    authors: Haentzschel I,Freiberg-Richter J,Platzbecker U,Kiani A,Schetelig J,Illmer T,Ehninger G,Schleyer E,Bornhäuser M

    更新日期:2008-07-01 00:00:00

  • Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.

    abstract::Calcineurin inhibitor (CNI)-sparing T-cell depleted (TCD) hematopoietic stem cell transplants (HSCTs) are presumed to be less nephrotoxic than conventional HSCTs. We evaluated incidence and risk factors for kidney failure and chronic kidney disease (CKD) in 231 TCD and 212 conventional HSCT recipients. Kidney failure ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.343

    authors: Glezerman IG,Devlin S,Maloy M,Bui M,Jaimes EA,Giralt SA,Jakubowski AA

    更新日期:2017-05-01 00:00:00